Verapamil: A Promising Agent for Circumvention of Multidrug-Resistance?
作者:
S. Harder,
期刊:
Onkologie
(Karger Available online 1991)
卷期:
Volume 14,
issue 3
页码: 212-217
ISSN:0378-584X
年代: 1991
DOI:10.1159/000216978
出版商: S. Karger GmbH
关键词: Verapamil;Multidrug-resistance;Clinical trials
数据来源: Karger
摘要:
Multidrug-resistance (mdr) of tumor cell-lines to several natural product cytotoxines (e.g. vinca alkaloids, podophyllotoxine derivatives and anthracycline derivatives) is often related to enhanced expression of transmembraneous P-glykoproteine (pgp), which is encoded in humans by the mdrl-gene. Pgp acts as an outward-flow pump (multi-drug-carrier) and lowers the intracellular concentrations of the abovementioned drugs. In vitro studies have shown that the calcium-antagonist verapamil can reverse mdr in many human or animal tumor cell-lines by blocking pgp, but in vivo reversal of drug resistance in animals could only be proved in some tumor lines. In a limited number of investigations, an impact of verapamil-coadministration on the tumor progression in patients with mdr was demonstrable for only a minor part of the treated subjects.
点击下载:
PDF
(3427KB)
返 回